VistaGen Therapeutics Inc. (NASDAQ: VTGN) Announces Positive Preclinical Data for Potential Anxiety Treatment
VTGN CEO “even more excited about PH94B's potential to change lives without the risky side effects and safety concerns of benzos” Study results suggest PH94B's mechanism of action may not have benzodiazepine-like side effects, such as sedation, cognitive impairment or abuse liability Company making significant progress in preparing PH94B for launch of pivotal Phase 3 study for acute treatment of anxiety in adults with social anxiety disorder VistaGen Therapeutics (NASDAQ: VTGN) has reported new preclinical findings differentiating the mechanism of action of PH94B from that of benzodiazepines (https://ibn.fm/Al4ur). PH94B is an intranasal neuroactive steroid VistaGen is preparing for Phase 3 development…